CAR T-CELL Therapy Educational Video Trial
NCT04280133 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80
Last updated 2023-01-26
Summary
The purpose of this study is to test a new educational video to help patients and doctors talk about CAR-T cell therapy, a treatment being used in cancer.
\- Educational video tool for patients receiving CAR-T cell therapy.
Conditions
- Hematologic Malignancy
- CAR-T Cell Therapy
Interventions
- BEHAVIORAL
-
Educational Video Tool
The video educational tool was written by the investigators in collaboration with a panel of experts on CAR T-cell therapy, medical ethicists, palliative care clinicians, and oncologists.
Sponsors & Collaborators
-
Massachusetts General Hospital
lead OTHER
Principal Investigators
-
Patrick C Johnson, MD · Massachusetts General Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-05-25
- Primary Completion
- 2022-10-26
- Completion
- 2023-02-24
Countries
- United States
Study Locations
More Related Trials
-
Response to Chimeric Antigen Receptor (CAR)-T Cells Therapy in Patients With Hematologic Malignancies Depending on Tumor Characteristics
NCT04209829 ·Status: NOT_YET_RECRUITING
-
Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33
NCT01864902 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
NCT02541370 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Immunological Parameters, Neurocognitive Changes, Activity, & Driving Fitness in Patients Undergoing CAR-T Cell Therapy
NCT04275154 ·Status: WITHDRAWN
-
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
NCT02935153 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
NCT03302403 ·Status: UNKNOWN ·Phase: NA
-
CAR-T Cellular Therapy for B Cell Malignancies Involved in CNS
NCT04287309 ·Status: UNKNOWN
-
Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
NCT01735604 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
CAR-T for Claudin18.2 Positive Solid Tumors
NCT07266311 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...
NCT05621291 ·Status: RECRUITING ·Phase: NA
-
CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions
NCT07048535 ·Status: RECRUITING
-
Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies
NCT02813837 ·Status: UNKNOWN ·Phase: NA
-
Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer Studies
NCT02666248 ·Status: COMPLETED
-
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
NCT06408194 ·Status: RECRUITING ·Phase: PHASE1
-
A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies
NCT02937103 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19
NCT01864889 ·Status: UNKNOWN ·Phase: NA
-
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
NCT04029038 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission
NCT05707273 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy
NCT07186192 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
NCT04025216 ·Status: TERMINATED ·Phase: PHASE1
-
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies
NCT04088864 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
NCT03064269 ·Status: RECRUITING ·Phase: PHASE1
-
Allogeneic UCB-derived CAR-T for B-ALL
NCT07256353 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
NCT02186860 ·Status: UNKNOWN ·Phase: PHASE1
-
CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
NCT07328503 ·Status: RECRUITING ·Phase: PHASE2